3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Neoplasms
3
Fallopian Tube Neoplasms
3
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Solid Tumor
1
Primary Myelofibrosis
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Metastatic Castration Resistant Prostate Cancer
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Leukemia
1
Leiomyosarcoma
1
Glioblastoma
1
Colorectal Neoplasms
1
Adenocarcinoma of the Oesophagus
1
ATM Gene Mutation
1
Interventions
Specimen Handling
3
olaparib
2
durvalumab
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Ipilimumab
2
CTLA-4 Antigen
2
serabelisib
1
sapanisertib
1
defactinib
1
ceralasertib
1
cediranib
1
capivasertib
1
cabozantinib
1
Restraint, Physical
1
RO5126766
1
Paclitaxel
1
Immunoglobulin G
1
Hysterectomy
1
Fluid Therapy
1
Disulfides
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Carcinoma, Endometrioid
×
rucaparib
×
1 year
×
Clear all
No trials found.